Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

FDA approves Jazz Pharmaceuticals' Ziihera (zanidatamab) as first-line HER2-targeted therapy for gastroesophageal adenocarcinoma based on Ph3 data
Antibody, cancer, bispecific antibody, gastric cancer, HER2 - Read more

Biohaven, SK Biopharmaceuticals partner on Kv7 epilepsy platform licensing deal worth up to $795M
Licensing deal, epilepsy, small molecule, milestone payments, ion channel - Read more

4basebio, Genezen collaborate to advance synthetic cell-free DNA platforms for viral vector manufacturing
Research collaboration, gene therapy, viral vector manufacturing, cell-free DNA, drug discovery - Read more

CDT Equity, Pep'd partner via SAFE note with $10M valuation cap to expand US peptide market exposure
Equity investment, peptide therapeutics, AI/ML, digital health, drug discovery - Read more

Cell and Gene Live is a one-day, investor & CEO summit dedicated exclusively to Cell and Gene therapy - the science, the manufacturing, and the investment driving advanced medicines forward. All happening on November 15, 2026.

(Hosted by Onyx at The Shard in London as part of London Life Sciences Week)

Speakers confirmed include:

• Steve Bates, OBE (Chair of the UK's Department of Life Sciences)
• Dr. Erik Wiklund (CEO of Circio)
• Edwin Stone (CEO of Cellular Origins)
+ many more!

Get your tickets here - for TLDR Biotech readers, use code ANIS20 at check-out for 20% off.

Summit Therapeutics, Akeso's (ivonescimab) beats Imfinzi in Ph3 trial for first-line biliary tract cancer in China
Antibody, cancer, bispecific antibody, biliary tract cancer, PD-1/VEGF, immunotherapy - Read more

JATT III Acquisition raises $60M IPO, SPAC seeking biotech or life sciences reverse merger target
SPAC, AI/ML platform, drug discovery, computational biology, biotech - Read more

Addex Therapeutics raises $2.8M via ATM offering, extending cash runway to Q4 2027
Clinical-stage, small molecule, neurological, allosteric modulators - Read more

Solvonis Therapeutics raises £1.3M, advancing CNS disorder clinical and regulatory milestones
CNS disorders, small molecule, clinical-stage, neurological - Read more

Transfyr Bio raises $25M Seed funding, building AI infrastructure platform for laboratory science
AI/ML platform, laboratory science, software platform, data analytics - Read more

Labcorp launches hepatitis D reflex test to improve detection among hepatitis B-positive patients
Diagnostics, infectious disease, operational, competitive - Read more

Eisai, Biogen launch Leqembi Iqlik subcutaneous autoinjector in US for early Alzheimer's treatment
Monoclonal antibody, Alzheimer's disease, operational, competitive - Read more

FDA considers adding two deputy commissioner roles focused on AI/health and drugs
FDA leadership, AI in healthcare, operational, regulatory - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Bristol Myers Squibb terminates $380M CAR-T manufacturing deal with Cellares over Breyanzi scale-up failure
Manufacturing agreement, cell therapy, CAR-T, oncology, commercialization - Read more

Spyre Therapeutics' (SPY072) anti-TL1A antibody fails Ph2 goals for rheumatoid arthritis monotherapy development
Antibody, autoimmune, monoclonal antibody, rheumatoid arthritis, TL1A, anti-TL1A - Read more

Teva faces Turkey antitrust probe over alleged generic competition restrictions tied to Copaxone patents
Small molecule, autoimmune/neurological, antitrust, competitive, operational - Read more

Baxter recalls two products over fiberglass and stainless steel particulate contamination concerns
Small molecule, cardiovascular, operational, safety recall - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here